FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure

Frank Vinluan / medcitynews - AstraZeneca’s Baxfendy is the first FDA-approved drug in a new class of medicines called aldosterone synthase inhibitors. The new mechanism of action is important for patients and for AstraZeneca, which has been looking for new drugs with blockbuster pote…

AI Summary: The FDA has approved a first-in-class oral agent that uses a novel mechanism to lower resistant hypertension, offering an alternative for patients who haven’t responded to standard therapies. The move expands treatment options and signals renewed industry focus on innovative vascular targets — finally something for stubborn blood pressure to complain about.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Denali drug receives accelerated approval for rare CNS indication / 2 months

Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 6 wks

FDA clears first once‑weekly basal insulin for Type 2 diabetes / 2 months

FDA approves Rocket Pharma gene therapy for ultra‑rare immune disorder / 2 months

FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 4 months

FDA rejects Corcept’s cortisol modulator triggering setback / 4 months

FDA approves Rucaparib for advanced prostate cancer / 5 months